July 2025 – KD Pharma Group (“KD Pharma”), a leading CDMO in pharmaceutical and nutritional lipids, announces the acquisition of dsm-firmenich’s Marine Lipids business. As part of the transaction, dsm-firmenich will obtain a minority stake in KD Pharma and become co-shareholder alongside the capiton Omega continuation fund vehicles and other minority shareholders.
The transaction will close in the course of 2024 subject to customary regulatory approvals, and includes dsm-firmenich’s Marine Lipids fish oil omega-3 business for the dietary supplement and pharma markets, together with the production facilities in Piura, Peru, and Mulgrave, Canada.
This transaction will create a well-equipped market player in marine lipids by combining the best of the two companies and respective expertise, with the scale of dsm-firmenich’s Piura and Mulgrave sites and the high concentration capability of KD Pharma. The enlarged KD Pharma Group will benefit from the expansion into a significantly wider range of products and customization opportunities supported by broadened manufacturing capacity.
Oscar Groet, CEO of KD Pharma said, “We are thrilled to welcome dsm-firmenich’s Marine Lipids portfolio into KD Pharma, a move that aligns perfectly with our strategic vision of being technology leaders in lipids and enhancing our ability to innovate and deliver exceptional value to our customers.”
For more information, visit KD Pharma Group News
capiton AG and KD Pharma Group were advised by Jefferies, acting as buyside advisor, CMS Hasche Sigle, Baker McKenzie, A&O Shearman, EY, BDO, Herter & Co. – A Teneo Company, Roland Berger and Howden M&A. The transaction was notarized by Dr. Patrick Auerbach (NEON) and is subject to customary regulatory approvals.
